This post has been archived and contains information that may be out of date.
Following the approval by the U.S. Food and Drug Administration (FDA) of emergency use authorization for the investigational monoclonal antibody therapy, bamlanivimab, the Centers for Medicare & Medicaid Services (CMS) announced it will cover monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency.
This content is restricted to members.
